$TXG News

10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade)

Stephens & Co. Maintains Overweight on 10x Genomics, Raises Price Target to $65

Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $47

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $60

Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $50

Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $40

10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript

10x Genomics Raises FY2026 Sales Guidance from $600.000M-$625.000M to $610.000M-$630.000M vs $613.851M Est

10x Genomics Q2 EPS $(0.14) Beats $(0.24) Estimate, Sales $151.000M Beat $146.788M Estimate

10x Genomics Partners With Lausanne University Hospital On Diagnostic Applications Of Single Cell And Spatial Technologies For Cancer Care

Leerink Partners Maintains Market Perform on 10x Genomics, Raises Price Target to $40

10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026

Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $50

Does 10x Genomics (TXG) Leaving Russell Value Indexes Reframe Its Growth Versus Profitability Story?

Is 10x Genomics (TXG) Overvalued Following Its Earnings Beat?

Morgan Stanley Maintains Equal-Weight on 10x Genomics, Raises Price Target to $37

10x Genomics (TXG) Stock Looks Reasonable On Cash Flow But Rich On Sales

Life Sciences Tools & Services Stocks Q1 Results: Benchmarking 10x Genomics (NASDAQ:TXG)

Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $45

Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $42